Robinson continued, ???This reverse merger allows TechniScan to become a publicly traded company, which we believe will help us continue to raise the funds needed to make refinements in our imaging system and introduce a commercial version within the next year. We expect that these developments will create broader opportunities for TechniScan, and our European partner, Esaote (www.esaote), in the use of automated ultrasound as another effective imaging tool to help radiologists more effectively detect and diagnose breast cancer.???

???In light of October being Breast Cancer Awareness Month,??? added Robinson, ???I think this is a propitious time for TechniScan to become a publicly traded company.???

TechniScan has raised more than $24 million in equity financing and $5 million in federal grant funding from the National Institutes of Health (NIH) and the National Cancer Institute (NCI), bringing the total raised to approximately $29 million.

TechniScan grew out of the University of Utah, Department of Bioengineering. TechniScan developed the Svara?„? technology with the support of the Governor's Office of Economic Development (GOED) Centers for Excellence Program in Utah, the National Institute of Health (NIH), and the National Cancer Institute (NCI). TechniScan??™s Warm Bath Ultrasound (WBU?„?) imaging device (Svara?„?) is limited by US law to investigational use unless and until cleared by the FDA.

Source: TechniScan, Inc.